Dendreon Announces Data Presentation at the 2012 American Urological Association Annual Meeting - Yahoo Finance

May 21, 2012–Dendreon Corporation (NASDAQ: DNDN) today announced the following PROVENGE® (sipuleucel-T) data will be presented at the American Urological Association (AUA) Annual Meeting taking place May 19 – 23, 2012 in Atlanta ...

Dendreon: Data Continue To Support Provenge's Overall Survival Benefit - Benzinga

Dendreon Corporation (NASDAQ: DNDN) today announced the following PROVENGE® (sipuleucel-T) data will be presented at the American Urological Association (AUA) Annual Meeting taking place May 19 – 23, 2012 in Atlanta, Georgia. “Sipuleucel-T in African ...

Dendreon Presents Provenge Data - Analyst Blog - NASDAQ

Dendreon Corporation ( DNDN) recently announced the presentation of Provenge (sipuleucel-T) data at the American Urological Association (AUA) annual meeting.  At the AUA meeting, two topics were presented by Dendreon on Provenge. A subgroup ...

Dendreon Corporation : Dendreon Announces Data Presentation at the 2012 American Urological Association Annual Meeting - 4-traders (press release)

May 21, 2012-Dendreon Corporation (NASDAQ: DNDN) today announced the following PROVENGE® (sipuleucel-T) data will be presented at the American Urological Association (AUA) Annual Meeting taking place May 19 - 23, 2012 in Atlanta, Georgia. "Sipuleucel-T in ...

Dendreon Announces Presentation of PROVENGE Data at the 2012 American Society of Clinical Oncology Annual Meeting - Marketwatch

SEATTLE, May 16, 2012 (BUSINESS WIRE) -- May 16, 2012--Dendreon Corporation (NASDAQ:DNDN) today announced the following PROVENGE(R) (sipuleucel-T) data will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting taking ...

AUA2012 And Dendreon: Provenge's Extended Survival And Efficacy For African Americans - Seekingalpha.com

As noted by the authors, in the IMPACT study (n=512), there was a 4.1-month improvement in median OS (25.8 vs. 21.7months) for sipuleucel-T compared with control (HR=0.78; 95% CI: 0.61, 0.98; p=0.032). Importantly, 109/171 (64%) of control patients received APC8015F.

Dendreon Reports Fourth Quarter and 2011 Year End Financial Results - Yahoo Finance

At the end of the fourth quarter, completed in-servicing for more than 840 total sites, of which: More than 590 sites have infused PROVENGE® (sipuleucel-T). Approximately 615 sites have either infused the product or have their patients ...

Prostate Cancer Tops News in Humdrum ASCO Abstract Release - Phramalive.com

Should Zytiga gain approval in the pre-chemotherapy population, it would go head-to-head with Dendreon’s slow-to-launch -- and far more expensive -- prostate cancer vaccine Provenge (sipuleucel-T). Adding to the mix is Medivation Inc.’s MDV3100 ...

Treatment Options in Castration-Resistant Prostate Cancer - Medscape News

The sipuleucel-T work [4] with this cellular active immunotherapy is very interesting and is probably one of the very first trials that has been positive with any kind of immune therapy in treating advanced cancer. This whole area of ...

Dendreon Reports Net PROVENGE Product Revenues of $82 Million, Achieved 6.5% Quarter-Over-Quarter Growth - Phramalive.com

Dendreon's first product, PROVENGE® (sipuleucel-T), was approved by the U.S. Food and Drug Administration (FDA) in April 2010. Dendreon is exploring the application of additional ACI product candidates and small molecules for the potential treatment of a ...